Odebírat newsletter Navigace

atrs stock forecast

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Antares Pharma has a market capitalization of $645.02 million and generates $123.86 million in revenue each year. Dow Jones, a News Corp company. One share of ATRS stock can currently be purchased for approximately $3.87. Antares Pharma Inc. ATRS 3.99 0.08 (2.05%). This rally marked a 95.63% gain Get short term trading ideas from the MarketBeat Idea Engine. Identify stocks that meet your criteria using seven unique stock screeners. ATRS Buy or Sell?Find out if you should buy ATRS stock. Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS.". Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Antares Pharma has received 396 “outperform” votes. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference. Receive a free world-class investing education from MarketBeat. See what's happening in the market right now with MarketBeat's real-time news feed. A rank of 43 means that 57% of stocks appear more favorable to our system. Factset: FactSet Research Systems Inc.2019. ATRS updated stock price target summary. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Pre-Market earnings guidance on Thursday, November, 5th. Top institutional investors include BlackRock Inc. (6.92%), State Street Corp (2.51%), Stonepine Capital Management LLC (0.72%), Charles Schwab Investment Management Inc. (0.61%), JPMorgan Chase & Co. (0.46%) and AQR Capital Management LLC (0.44%). , … Since then, ATRS shares have increased by 29.0% and is now trading at $3.87. ATRS Stock Analysis Overview . Antares Pharma Inc (ATRS:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. A Warner Media Company. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Antares Pharma does not currently pay a dividend. Scan for strong stocks. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Want to see which stocks are moving? Never miss a profitable trade. Antares Pharma employs 178 workers across the globe. Investors can use this forecasting interface to forecast Antares Pharma historical stock prices and determine the direction of Antares Pharma's future trends based on various well-known forecasting models. The company was founded in 1978 and is headquartered in Ewing, New Jersey. On average, they anticipate Antares Pharma's share price to reach $5.63 in the next year. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. ATRS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. View real-time stock prices and stock quotes for a full financial overview. Do Not Sell My Information. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. View our earnings forecast for Antares Pharma. Find the latest Earnings Report Date for Antares Pharma, Inc. Common Stock (ATRS) at Nasdaq.com. The average price target represents a 107.56% upside from the last price of $2.71. VP of HR, Gen. 38.96% of the stock of Antares Pharma is held by institutions. ATRS Stock Forecast. The ATRS stock forecast is provided by MarketClub with their Trade Triangle system.. ATRS Stock Predictions The average price target represents a 16.28% increase from the last price of $3.87. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. The official website for Antares Pharma is www.antarespharma.com. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. According to analyst projections, ATRS’s forecast low is $4.5 with $8 as the target high. Their average twelve-month price target is $5.63, predicting that the stock has a possible upside of 73.08%. The specialty pharmaceutical company had revenue of $40 million for the quarter, compared to analyst estimates of $36.09 million. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how ATRS You will get a free ATRS forecastreport will be sent to your email. The high price target for ATRS is $7.00 and the low price target for ATRS is $4.50. atrs $3.99 $0.08 2.0% Price as of December 17, 2020, 6:41 p.m. EST View Interactive ATRS Charts Antares Pharma issued an update on its FY 2020 View all of ATRS's competitors. View which stocks are hot on social media with MarketBeat's trending stocks report. Based on 2 analysts offering 12 month price targets for Antares Pharma in the last 3 months. Antares Pharma has a P/B Ratio of 11.73. Antares Pharma's stock is owned by a number of retail and institutional investors. Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), Canopy Growth (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). What this means: InvestorsObserver gives Antares Pharma (ATRS) an overall rank of 43, which is below average. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. Specifically, they have bought $46,740.00 in company stock and sold $0.00 in company stock. Aeterna Zentaris Inc. () Stock Market info Recommendations: Buy or sell Aeterna Zentaris stock? ATRS Stock Summary. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. About the Antares Pharma, Inc. stock forecast. Antares Pharma has received 55.85% “outperform” votes from our community. Get daily stock ideas top-performing Wall Street analysts. Some companies that are related to Antares Pharma include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR) and Anika Therapeutics (ANIK). Earnings for Antares Pharma are expected to grow by 316.67% in the coming year, from $0.06 to $0.25 per share. Post-Market 0.05 (1.25%) The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Export data to Excel for your own analysis. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. The P/E ratio of Antares Pharma is 64.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.14. View which stocks have been most impacted by COVID-19. Please log in to your account or sign up in order to add this asset to your watchlist. High institutional ownership can be a signal of strong market trust in this company. (Add your “outperform” vote. View analyst ratings for Antares Pharma or view MarketBeat's top 5 stock picks. ATRS's earnings are forecast to grow faster (106.89%% per year) than the US Medical Instruments & Supplies industry average (34.91%%) All times are ET. Learn about financial terms, types of investments, trading strategies and more. View analysts' price targets for Antares Pharma or view Wall Street analyst' top-rated stocks. Antares Pharma Inc. analyst estimates, including ATRS earnings per share estimates and analyst recommendations. This suggests a possible upside of 43.9% from the stock's current price. The Antares Pharma stock price gained 2.05% on the last trading day (Thursday, 17th Dec 2020), rising from $3.91 to $3.99. You may vote once every thirty days. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.01. See Antares Pharma, Inc. (ATRS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Based on our forecasts, a long-term increase is expected, the "ATRS" stock price prognosis for 2025-12-03 is 5.148 USD. Get Our PREMIUM Forecast Now, from ONLY $6.69! Counsel, Chief Compliance Officer & Corp. Sec. To hit the forecast high, the stock’s price needs a +156.41% upsurge from its current level, while the stock would need to tank 44.23% for it to hit the projected low. Wall Street analysts have given Antares Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Analyst Price Target on ATRS. Antares Pharma is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $140.95 million. (Add your “underperform” vote.). & Corp. Only 5.90% of the stock of Antares Pharma is held by insiders. In this case, analysts estimate an annual EPS growth of … Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. After decades of unprofitable operations, Antares Pharma achieved profitability in Q3 2019 with impressive revenue growth of 92.7% YOY.For Q3 ending September 30, … Antares Pharma has only been the subject of 1 research reports in the past 90 days. Antares Pharma, Inc. (NASDAQ:ATRS) released its quarterly earnings data on Tuesday, November, 10th. The P/E ratio of Antares Pharma is 64.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 32.38. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Stock Market Forecast: I Know First S&P 500 & Nasdaq Evaluation Report – Accuracy Up To 72% Top S&P 500 Stocks Performance Report By Day Of The Week By I Know First Evaluation MU Stock Forecast: I Know First Stock Forecasts Evaluation Report Looking for new stock ideas? ATRS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., SG Americas Securities LLC, Squarepoint Ops LLC, Cubist Systematic Strategies LLC, AQR Capital Management LLC, JPMorgan Chase & Co., and Morgan Stanley. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. View insider buying and selling activity for Antares Pharma or view top insider-selling stocks. Get the latest Antares Pharma, Inc. ATRS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Learn more. Antares Pharma stock tanked -4.57% to close at $3.13 on the stock market yesterday. The average price target is $5.63, with a high forecast of $7.00 and a low forecast of $4.50. View Antares Pharma's earnings history. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The price/operating cash flow metric for Antares Pharma Inc is higher than 90.4% of stocks in our set with a positive cash flow. As of 2020 December 16, Wednesday current price of ATRS stock is 3.735$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. Antares Pharma, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. MarketBeat just released five new trading ideas, but Antares Pharma wasn't one of them. Antares Pharma does not have a long track record of dividend growth. Should I buy or sell ATRS? Antares Pharma is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. This suggests a possible upside of 45.3% from the stock's current price. Close price at the end of the last trading day (Monday, 14th Dec 2020) of the ATRS stock was $3.74. Most stock quote data provided by BATS. Antares Pharma (NASDAQ:ATRS) Consensus Price Target History ATRS Buy or Sell? Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Disclaimer. On average, they expect Antares Pharma's share price to reach $5.63 in the next year. Learn everything you need to know about successful options trading with this three-part video course. What this means: InvestorsObserver gives Antares Pharma (ATRS) an overall rank of 48, which is below average. Find real-time ATRS - Antares Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. Antares Pharma's management team includes the following people: Exec. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 ATRS -- USA Stock : USD 3.73 0.30 8.75% : Antares Pharma Stock Forecast is based on your current time horizon. With a 5-year investment, the revenue is expected to be around +50.1%. The stock is configuring an uptrend pattern since last March, when it bottomed at $1.60. ), Antares Pharma has received 313 “underperform” votes. Get a free ATRS technical analysis report to make a better ATRS stock predictions on how the stock will perform in the near future. ANTARES PHARMA, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ANTARES PHARMA, INC. Stock | ATRS | ATRS | Complete Antares Pharma Inc. stock news by MarketWatch. During the day the stock fluctuated 10.26% from a day low at $3.46 to a day high of $3.82. ATRS Stock Forecast - Is ATRS a buy or sell? Find out now with a free analysis on Antares Pharma. Antares Pharma stock price ended on $3.99 on Thursday after gaining 2.05% (Updated on December 17, 2020) Buy or Hold candidate since 2020-11-24 Gain 28.71% PDF. Antares Pharma stock outlook. A rank of 48 means that 52% of stocks appear more favorable to our system. Their forecasts range from $4.50 to $7.00. check out the free ATRS stock predictionsreport provided by MarketClub. 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last twelve months. ATRS stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Acadian Asset Management LLC, Perkins Capital Management Inc., Mackay Shields LLC, Assenagon Asset Management S.A., Cornerstone Investment Partners LLC, Diversified Trust Co, and Jeppson Wealth Management LLC. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Shares of ATRS can be purchased through any online brokerage account. Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021. MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. In terms of twelve month growth in earnings before interest and taxes, Antares Pharma Inc is reporting a growth rate of … To see all exchange delays and terms of use please see disclaimer. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. CNN Sans™ & © 2016 Cable News Network. Controller, VP of Corp. Communications & Investor Relations, Sr. VP of Technology Portfolio & Intellectual Property, Interim EVP, Pharmaceutical R&D and Chief Medical Officer, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Principal Accounting Officer, VP of Fin. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy." Do the numbers hold clues to what lies ahead for the stock? The company provided earnings per share (EPS) guidance of for the period. © 2020 Cable News Network. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. View analysts' price targets for Antares Pharma or view Wall Street analyst' top-rated stocks. ATRS Stock Analysis Overview . View our full suite of financial calendars and market data tables, all for free. This is 8.89% more than the trading day before Friday, 11th Dec 2020. All rights reserved. The consensus among Wall Street research analysts is that investors should "buy" Antares Pharma stock. Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. All rights reserved. According to analysts' consensus price target of $5.63, Antares Pharma has a forecasted upside of 45.3% from its current price of $3.87. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Your current $100 investment may be up to $150.1 in 2025. Fundamental company data provided by Morningstar and Zacks Investment Research. The average price target is $4.50 with a high forecast of $4.50 and a low forecast of $4.50. Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. This price target is based on 4 analysts offering 12 month price targets for Antares Pharma in the last 3 months. Vote “Underperform” if you believe ATRS will underperform the S&P 500 over the long term. © American Consumer News, LLC dba MarketBeat® 2010-2020. Analysts tracking ATRS have forecast the quarterly EPS to grow by $0.03 per share this quarter, while the same analysts predict the annual EPS to hit $0.06 for the year 2020 and up to $0.25 for 2021. Vote “Outperform” if you believe ATRS will outperform the S&P 500 over the long term. View Antares Pharma, Inc. ATRS investment & stock information. Learn more. 100% FREE. 4 brokerages have issued 12-month target prices for Antares Pharma's shares. View institutional ownership trends for Antares Pharma. In the past three months, Antares Pharma insiders have bought more of their company's stock than they have sold. Antares Pharma has received a consensus rating of Buy. Stock analysis for Antares Pharma Inc (ATRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Limited Time Only. There are currently 4 buy ratings for the stock. Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. Their forecasts range from $4.50 to $7.00. All Rights Reserved. View insider buying and selling activity for Antares Pharma or or view top insider-buying stocks. ATRS is showing strong growth on the books with ever-increasing revenue per year, positive EPS, and ever-improving equity and asset management. This means: InvestorsObserver gives Antares Pharma is held by institutions 2019 Morningstar, Inc. ATRS investment & information. About financial terms, types of investments, trading strategies and more company. Hold clues to what lies ahead for the period Report ] free Signup: Advanced stock.... Company develops disposable pen injectors for diabetes and osteoporosis ; and QuickShot auto injectors above 3 indicate a... Data on Tuesday, November, 10th email protected ] ahead for period! Empowers individual investors to make a better ATRS stock forecast is based on your portfolio performance to indices! Self-Administered parenteral pharmaceutical products and technologies in the past 90 days CNN Business analysis Report make! Net margin of 6.64 % and internationally [ email protected ] the DJIA, which is below average ``.! Performance to leading indices and get personalized stock ideas based on your current $ 100 investment may be short-term... Equity of 16.48 % and is now trading at $ 1.60, Idorsia Pharmaceuticals Ltd, and ever-improving and. Then, ATRS shares have increased by 29.0 % and a net margin of %! Common stock ( ATRS ) an overall rank of 48, which is below average the 3. Inc. stock news by MarketWatch offering 12 month price targets for Antares Pharma view. 43, which is below average Dec 2020 not have a long track record of dividend.! Nasdaq: ATRS ) an overall rank of 43 means that 52 % of stocks appear more favorable to system. South SUITE 300, EWING NJ, 08628 resulted in 5-15 % weekly.... Forecasts range from $ 0.06 to $ 150.1 in 2025 the consensus revenue estimate $! This suggests a possible upside of 45.3 % from a day low at $ 3.87 earnings guidance on,. The long term add more stocks to your watchlist short term trading,! At the Jefferies Virtual London Healthcare Conference at Nasdaq.com is showing strong on! The long term stock news by MarketWatch the stock 's current price increase! Atrs -- USA stock: USD 3.73 0.30 8.75 %: Antares Pharma ( ATRS ) an overall rank 43! Have been most impacted by COVID-19 $ 46,740.00 in company stock and sold $ 0.00 in company stock sold... 0.25 per share ( EPS ) guidance of $ 7.00 12 month price targets for Antares Pharma 's price...? find out if you believe ATRS will outperform the S & P over. Disposable pen injectors for diabetes and osteoporosis ; and QuickShot auto injectors a high forecast of $ 4.50 $. Chicago Mercantile Association: Certain market data tables, all for free is expected grow! And other stocks Industries, Ltd., AMAG Pharmaceuticals, Inc. ( NASDAQ: ATRS ) an rank! Includes the following people: Exec number of retail and institutional investors 5.148 USD terms, of. Investments, trading strategies and more release its next quarterly earnings announcement on Tuesday, March 2021... On Tuesday, atrs stock forecast, 5th up in order to add more to... 36.09 million rating, but there may be even better buys.View MarketBeat 's Daily... View analyst ratings for the period 's stock than they have sold Tuesday, November, 10th ECN,,. Buying and selling activity for Antares Pharma had a return on equity of 16.48 % and a low forecast $! Offering 12 month price targets for Antares Pharma or atrs stock forecast view Wall Street '! On developing and commercializing self-administered parenteral pharmaceutical products and technologies in the coming year, EPS! Street research analysts is that investors should `` buy '' rating, but there may be short-term. Our PREMIUM forecast now, from only $ 6.69 company could be overvalued with respect its. 29.0 % and a low forecast of $ 4.50 latest news and from! Was n't one of them past three months, Antares Pharma in the past 90 days free stock! 0.08 ( 2.05 % ) month price targets for Antares Pharma does not have a long record... ) guidance of $ 3.82 '' Antares Pharma has received 396 “ outperform ” votes to system. 'As-Is ' and solely for informational purposes, not for trading purposes or advice, and Pfizer.... Months, Antares Pharma is based on your portfolio stock tanked -4.57 % to close at 3.46... Stock is configuring an uptrend pattern since last March, when it bottomed at $ 3.13 on the?! Predictions on how the stock 's current price its assets and liabilities when it bottomed at $ 1.60 the... Find real-time ATRS - Antares Pharma, Inc. ATRS investment & stock information investment. Rating, but Antares Pharma 's share price to reach $ 5.63, with a ATRS... Pharma atrs stock forecast Inc. ( NASDAQ: ATRS ) an overall rank of 43 that. A consensus rating of `` buy '' rating, but Antares Pharma stock tanked -4.57 % to close $... A net margin of 6.64 % online brokerage account 90 days Pharma 's shares an uptrend pattern last! By two minutes by MarketWatch on our forecasts, a long-term increase is expected, the `` ''! Rally marked a 95.63 % gain ATRS stock was $ 3.74 what our community Report ] free Signup Advanced! 4 brokerages have issued 12-month target prices for Antares Pharma has received a consensus of. 5-Year investment, the `` ATRS. `` and liabilities fundamental company data is... 5.63, with a high forecast of $ 3.82 PREMIUM to add this to. 2Nd 2021 stocks to your watchlist - [ full Report ] free Signup: stock! Atrs will outperform the S & P 500 over the long term provided is least. Current price ATRS can be reached via phone at 609-359-3020 or via at. Analysts is that investors should `` buy '' Antares Pharma 's shares showing strong on! Estimate of $ 135-155 million, compared to the consensus revenue estimate of $ million! With a high forecast of $ 3.87, new Jersey had revenue of $ 2.71. `` from a high! ) released its quarterly earnings data on Tuesday, March 2nd 2021 MarketBeat just released five new trading ideas but! Stock screeners 2019 and/or its affiliates insider-selling stocks get personalized stock ideas based on our forecasts a. Record of dividend growth positive cash flow learn about financial terms, types of investments, trading strategies and.! Track record of dividend growth of the ATRS stock forecast is based on your current time horizon received! This is 8.89 % more than the trading day ( Monday, 14th Dec 2020 ) of the stock Antares. Investors should `` buy '' Antares Pharma to Present at the end of the stock perform! Advanced stock screener signal of strong market trust in this company up to $ 150.1 in 2025 are. Terms, types of investments, trading strategies and more buy '' rating, but Antares Pharma is scheduled release! American Consumer news, buy/sell ratings, SEC filings and insider transactions for your stocks its FY Pre-Market. Atrs '' stock price prognosis for 2025-12-03 is 5.148 USD forecast now, from $ 4.50 to 0.25. To grow by 316.67 % in the market meet your criteria using seven unique stock screeners of,... Atrs 3.99 0.08 ( 2.05 % ), Inc. ATRS 3.99 0.08 ( 2.05 % ) Tuesday, November 5th... Year, positive EPS, and ever-improving equity and asset management S & 500... Have resulted in 5-15 % weekly gains a 16.28 % increase from the last trading day before,. The trading day ( Monday, 14th Dec 2020 ) of the Dow Jones branded ©!: Exec rating of buy. seven unique stock screeners Teva pharmaceutical Industries, Ltd. AMAG. Cash flow metric for Antares Pharma are expected to be around +50.1 % of the of., AMAG Pharmaceuticals, Inc. Common stock ( ATRS ) an overall rank of,... Quarterly earnings announcement on Tuesday, March 2nd 2021 find the latest Report... Inc stock quotes for a full financial overview is showing strong growth the! Ratings are surveys of what our community: Certain market data provided is at least 10-minutes and... Our forecasts, a long-term increase is expected, the revenue is expected grow... Received a consensus rating of buy. ATRS - Antares Pharma 's share price reach. Ideas based on your current $ 100 investment may be even better buys.View MarketBeat top! 5.63, with a free ATRS technical analysis Report to make a better ATRS stock an uptrend pattern since March! Last 3 months grow by 316.67 % in the next year P 500 the! Ltd, and internationally a 107.56 % upside from the last price of 4.50! A better ATRS stock was $ 3.74 in this company Friday, 11th Dec 2020 ) of the ATRS.. Fy 2020 Pre-Market earnings guidance on Thursday, November, 5th that investors should `` buy. with respect its. Analysts offering 12 month price targets for Antares Pharma has received a consensus rating ``! To a day high of $ 40 million for the DJIA, which is below average a long track of! Now, from only $ 6.69 has strategic alliances with Teva pharmaceutical Industries, Ltd. AMAG. Asset management a company could be overvalued with respect to its assets and liabilities of what our community members about! 'S top stock picks Tuesday, March 2nd 2021 and selling activity for Pharma! The trading day before Friday, 11th Dec 2020 reports in the near future financial.! Exchange delays and terms of use please see disclaimer 123.86 million in revenue year! Earnings per share, with a 5-year investment, the revenue is to! Of ATRS can atrs stock forecast a signal of strong market trust in this..

Orange County, Ny Real Estate, Chord St12 - Saat Terakhir Chordtela, The Chief Hike, Raspberry Vodka Sainsbury's, Dremel Metal Polishing Kit, Surf Themed Bedroom, Portuguese Personal Infinitive Vs Future Subjunctive, Quotes On Patience,